Page last updated: 2024-10-22

altretamine and Cancer of Ovary

altretamine has been researched along with Cancer of Ovary in 209 studies

Altretamine: A hexamethyl-2,4,6-triamine derivative of 1,3,5-triazine.

Research Excerpts

ExcerptRelevanceReference
"A phase II study was performed of oral altretamine in 71 patients with ovarian carcinoma who entered clinical complete remission with CA125 levels less than 35 U/mL after initial or second-line chemotherapy, and relapsed more than 6 months later."9.08Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125. ( Brown, S; Coleman, R; Crawford, M; Evans, H; Johnson, J; Lambert, HE; Ledermann, J; Nelstrop, AE; Oster, W; Rustin, GJ, 1997)
"Eighty patients with advanced ovarian adenocarcinoma were treated in a prospective, randomized trial comparing a four-drug combination--hexamethylmelamine, cyclophosphamide, methotrexate and 5-fluorouracil--with the oral alkylating agent, melphalan."9.04Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. ( Anderson, T; Bender, RA; Canellos, GP; Chabner, BA; DeVita, VT; Fisher, RI; Hubbard, SP; Simon, RM; Young, RC, 1978)
"Lithium carbonate ameliorates neutropenia associated with cancer chemotherapy."7.67The effect of lithium carbonate on chemotherapy-induced neutropenia and thrombocytopenia. ( Herbst, AL; Makii, MM; Richman, CM; Weiser, PA, 1984)
"In women with advanced ovarian cancer, initial therapy with a cisplatin-based combination chemotherapy regimen resulted in higher clinical complete response rates and longer time to failure compared with initial therapy with a single, oral alkylating agent; however, the benefits of this approach were confined to women older than 50 years of age at diagnosis, and there was no significant difference in survival."6.68Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878. ( Carbone, P; Vogl, S; Wadler, S; Yeap, B, 1996)
"A phase II study was performed of oral altretamine in 71 patients with ovarian carcinoma who entered clinical complete remission with CA125 levels less than 35 U/mL after initial or second-line chemotherapy, and relapsed more than 6 months later."5.08Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125. ( Brown, S; Coleman, R; Crawford, M; Evans, H; Johnson, J; Lambert, HE; Ledermann, J; Nelstrop, AE; Oster, W; Rustin, GJ, 1997)
"Fifty-seven evaluable patients with advanced ovarian carcinoma were randomized to receive either a combination of hexamethylmelamine, cyclophosphamide, methotrexate and 5-fluorouracil (Hexa-CAF) or high-dose cyclophosphamide alone given intravenously intermittently."5.05Advanced ovarian carcinoma: a prospective and randomized clinical trial of cyclophosphamide versus combination cytotoxic chemotherapy (Hexa-CAF). ( Carmo-Pereira, J; Costa, FO; Henriques, E; Ricardo, JA, 1981)
"A prospective randomized study was conducted in women with suboptimal (greater than or equal to 3 cm residual) Stage III, Stage IV, and recurrent ovarian adenocarcinoma to determine if combination chemotherapy is more effective than melphalan alone in achieving remission and improving survival."5.05A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide in ovarian carcinoma. ( Blessing, JA; Buchsbaum, HJ; Homesley, HD; Leone, L; Miller, A; Morrow, CP; Omura, GA, 1983)
"Eighty patients with advanced ovarian adenocarcinoma were treated in a prospective, randomized trial comparing a four-drug combination--hexamethylmelamine, cyclophosphamide, methotrexate and 5-fluorouracil--with the oral alkylating agent, melphalan."5.04Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. ( Anderson, T; Bender, RA; Canellos, GP; Chabner, BA; DeVita, VT; Fisher, RI; Hubbard, SP; Simon, RM; Young, RC, 1978)
"Antitumor activity against advanced ovarian cancer was demonstrated in phase I trials and the drug was quickly incorporated into trials which utilized drug combinations."3.76Role of hexamethylmelamine in the treatment of ovarian cancer: where is the needle in the haystack? ( Clagett-Carr, K; Foster, BJ; Leyland-Jones, B; Marsoni, S; Simon, R, 1986)
"Lithium carbonate ameliorates neutropenia associated with cancer chemotherapy."3.67The effect of lithium carbonate on chemotherapy-induced neutropenia and thrombocytopenia. ( Herbst, AL; Makii, MM; Richman, CM; Weiser, PA, 1984)
"Leukopenia was the dose-limiting toxicity."2.70Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma. ( Bertelsen, K; Havsteen, H; Høyer, M; Jakobsen, A; Malmström, H; Sørensen, P, 2001)
" No dose-response relationships were evident above paclitaxel/altretamine 175/150 mg/m2."2.70A phase I study of paclitaxel and altretamine as second-line therapy to cisplatin regimens for ovarian cancer. ( Davy, M; Egorin, M; Ellis, A; Lüftner, D; Olver, I; Park, SH; Webster, L, 2001)
"Altretamine was administered at a dose of 260 mg/m2 orally for 14 days in a 28-day course."2.69Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial. ( Ball, H; Blessing, JA; Lentz, SS; Markman, M; Moore, D, 1998)
"27 patients with ovarian cancer FIGO stages IIc-IV were treated with carboplatin 7 x (glomerular filtration rate + 25) mg given intravenously on day 1 and hexamethylmelamine (HMM) 150 mg/m2 orally on days 2-15, every 28 days."2.68A phase II study of carboplatin and hexamethylmelamine as induction chemotherapy in advanced epithelial ovarian carcinoma. ( Baekelandt, M; Kristensen, GB; Tropé, C; Vergote, IB, 1995)
"In women with advanced ovarian cancer, initial therapy with a cisplatin-based combination chemotherapy regimen resulted in higher clinical complete response rates and longer time to failure compared with initial therapy with a single, oral alkylating agent; however, the benefits of this approach were confined to women older than 50 years of age at diagnosis, and there was no significant difference in survival."2.68Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878. ( Carbone, P; Vogl, S; Wadler, S; Yeap, B, 1996)
" The treatments were identical in dosage and schedule with the exception of the addition of HMM to one regimen."2.67A comparison of hexamethylmelamine (altretamine), cyclophosphamide, doxorubicin, and cisplatin (H-CAP) vs. cyclophosphamide, doxorubicin, and cisplatin (CAP) in advanced ovarian cancer. ( Greco, FA; Hainsworth, JD; Johnson, DH, 1991)
"Forty-six patients with recurrent ovarian cancer were reoperated, and cancer samples for the subrenal capsule assay (SRCA) were collected from 23 of them, whereas this test was not done in the remaining 23 control patients."2.67Subrenal capsule assay in selection of chemotherapy after operation for recurrent ovarian cancer. ( Venesmaa, P; Ylikorkala, O, 1991)
" This study demonstrates that the combination of DDP + HMM is an effective regimen for advanced ovarian carcinoma that yields response rates comparable to other more complex regimens, and that there is a dose-response relationship for DDP in ovarian cancer."2.67Hexamethylmelamine and low or moderate dose cisplatin with or without pyridoxine for treatment of advanced ovarian carcinoma: a study of the Eastern Cooperative Oncology Group. ( Cheuvart, B; Comis, RL; Davis, TE; Falkson, G; Fazzini, E; Horton, J; Kaplan, BH; Vogl, SE; Wiernik, PH; Yeap, B, 1992)
"Prednimustine can produce durable responses in advanced ovarian cancer using a schedule that results in negligible toxicity."2.66Randomised trial comparing prednimustine with combination chemotherapy in advanced ovarian carcinoma. ( Cornbleet, MA; Fletcher, S; Kerr, GR; Leonard, RC; Livingstone, JR; Smart, GE; Smyth, JF; Webb, JN, 1989)
"Clinical investigation of epithelial ovarian cancer must involve the precise definition of the lesion, careful application of new techniques, the objective evaluation of such techniques, the comparison of results in a randomized fashion with prior forms of therapy, careful pathological evaluation of the tumour, and the evaluation of toxicity to the patient."2.65Mayo Clinic experience with epithelial ovarian cancer. ( Decker, DG, 1983)
"The age adjusted death rate for ovarian cancer has remained unchanged for the past 20 years."2.64Advances in the staging and treatment of ovarian cancer. ( Fisher, RI; Young, RC, 1977)
"Ovarian cancer is increasingly recognized as a chronic disease whose treatment is often characterized by administration of multiple, sequential active agents, each of which may or may not be accompanied by a tumor response."2.42Recurrent ovarian cancer: how important is it to treat to disease progression? ( Herzog, TJ, 2004)
"The standard treatment for ovarian cancer is cytoreductive surgery followed by platinum-based combination chemotherapy."2.39[Chemotherapy for recurrent ovarian cancer]. ( Chang, C; Imamura, K; Nishimura, H, 1996)
"Altretamine is a National Cancer Institute-designated group C antineoplastic agent used in the treatment of advanced ovarian cancer."2.38Altretamine. ( Hansen, LA; Hughes, TE, 1991)
"Two patients diagnosed with stage IIIC ovarian cancer underwent optimal cytoreductive surgery."1.32Oral altretamine used as salvage therapy in recurrent ovarian cancer. ( Berman, ML; Chan, JK; Loizzi, V; Manetta, A, 2004)
" Relative dose intensity was calculated as a fraction of the dosage of a drug in the standard regimen of cyclophosphamide, altretamine, doxorubicin, and platinum (CHAP)."1.29Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis. ( Hryniuk, W; Levin, L; Simon, R, 1993)
"The lack of decisive progress in ovarian cancer chemotherapy in recent years led the ARTAC "Ovary" group to initiate a study based on the hypothesis of collateral sensitivities."1.28[Study of vinorelbine (V) combined with hexamethylmelamine (H) (combination V-H) in adenocarcinoma of the ovary: results a phase I-IIA trial, NHO-88, of ARTAC "ovarian" group]. ( Coiffier, B; Facchini, T; Filippi, MH; Goudier, MJ; Goupil, A; Mignot, L; Pinel, MC; Pinon, G; Roullet, B; Tresca, P, 1991)
"Fifty-two patients with advanced ovarian cancer were treated with single-agent hexamethylmelamine (HMM), 260 mg/m2 po per day for 14 days followed by 14 days off drug."1.28Hexamethylmelamine as a single second-line agent in ovarian cancer. ( Larson, JE; Lyter, JA; MacNeill, C; Manetta, A; Podczaski, ES; Scheffler, B; Schein, P, 1990)
" This approach does not assume that the underlying dose-response curve is steep; nor does it assume that maximally dose-intense regimens are clinically appropriate in all situations."1.28Selecting drug combinations based on total equivalent dose (dose intensity) ( Korn, EL; Simon, R, 1990)
" The treatment regimens were identical in dosage and schedule with the exception of the addition of HMM to one regimen."1.28The role of hexamethylmelamine in the combination chemotherapy of advanced ovarian cancer: a comparison of hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin (H-CAP) versus cyclophosphamide, doxorubicin, and cisplatin (CAP). ( Burnett, LS; Greco, FA; Hainsworth, JD; Johnson, DH; Jones, HW, 1990)
"In patients with advanced ovarian cancer, initial treatment with combination chemotherapy, including cyclophosphamide and cis-platinum diamminedichloride (cis-platinum), produces response and progression-free survival results which are superior to those achieved with alkylating single-agent chemotherapy."1.27Current status of systemic chemotherapy in the treatment of advanced ovarian cancer with emphasis on CHAP-5. ( Neijt, JP; Pinedo, HM; ten Bokkel Huinink, WW; van der Burg, ME; van Oosterom, AT; Vriesendorp, R, 1984)
"Eighteen women with bulky ovarian cancer at the start of chemotherapy were brought to second laparotomy after 6 months of combination chemotherapy in an effort to resect previously unresectable tumor masses."1.27"Second-effort" surgical resection for bulky ovarian cancer. ( Calanog, A; Camacho, F; Greenwald, E; Kaplan, BH; Moukhtar, M; Seltzer, V; Vogl, SE, 1984)
"Of 89 samples of cancer cells from ovarian cancer patients primary cultures representative of the cancer cell population could be established in 17."1.27Clinical correlates of in vitro drug sensitivities of ovarian cancer cells. ( Erba, E; Garattini, S; Ghelardoni, C; Landoni, F; Mangioni, C; Morasca, L; Sessa, C; Vaghi, M, 1983)
"Thirty-eight women with advanced ovarian cancer were given monthly cycles of intravenous cyclophosphamide, Adriamycin (doxorubicin) and cis-platin, and oral hexamethylmelamine."1.27Cis-platin based combination chemotherapy for advanced ovarian cancer. High overall response rate with curative potential only in women with small tumor burdens. ( Arseneau, J; Bennett, B; Greenwald, E; Kaplan, BH; Pagano, M; Vogl, SE, 1983)
"With regard to colony formation of ovarian cancer according to the source of the specimen, the colony-forming rate of solid tumor was high (72%) as compared with 63% for ascites and 43% for pleural effusion."1.27[Chemotherapy testing for human ovarian cancer using in vitro colony assay]. ( Inoue, K, 1985)
" Further phase I studies, with different PMM dosage schedules, are necessary before phase II studies can be recommended."1.27Hexamethylmelamine and pentamethylmelamine: an update. ( Hahn, DA, 1983)
"A series of eight human ovarian cancer lines grown in nude mice were used to compare the activity of hexamethylmelamine (HMM) and N2,N4,N6-trihydroxy methyl-N2,N4,N6-trimethylmelamine (trimelamol)."1.27Superior efficacy of trimelamol to hexamethylmelamine in human ovarian cancer xenografts. ( Boven, E; Erkelens, CA; Nauta, MM; Pinedo, HM; Schlüper, HM, 1986)
"For 129 ovarian cancer patients failing prior chemotherapy, overall clinical response rates were: 21% with cisplatin, 36% with cisplatin plus doxorubicin, 52% with cyclophosphamide added to the two drugs, and 44% with hexamethylmelamine added to the three drugs."1.27Prognostic factors: cisplatin regimens for patients with ovarian cancer after failure of chemotherapy. ( Bruckner, HW; Cohen, CJ; Feuer, E; Holland, JF; Kabakow, B; Wallach, RC, 1987)
"Fifty-five ovarian cancer patients receiving platinum drug-based chemotherapy have been studied prospectively to determine the extent of formation of the bidentate intrastrand adducts of diammineplatinum covalently attached to the N7 positions of adenosine and/or guanosine in leukocyte DNA."1.27Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy. ( Ozols, RF; Poirier, MC; Reed, E; Tarone, R; Yuspa, SH, 1987)
"Phenytoin levels were reduced to 37% of the original values, although the drug was given intravenously."1.27An interaction between cytostatic and anticonvulsant drugs. ( de Voogd-van der Straaten, I; Neef, C, 1988)
"Eleven women with advanced ovarian cancer treated postoperatively with combination chemotherapy (cytoxan, hexamethylmelamine, Adriamycin, and cis-platinum) had disease-free intervals of 5 to 46 months (mean: 22 months) and subsequently developed recurrent carcinoma."1.27Recurrent ovarian carcinoma: retreatment utilizing combination chemotherapy including cis-diamminedichloroplatinum in patients previously responding to this agent. ( Kaplan, B; Seltzer, V; Vogl, S, 1985)
"Treatment of patients with advanced ovarian cancer who have failure of first-line chemotherapy is rarely effective."1.27Intraperitoneal chemotherapy for advanced ovarian cancer. ( Howell, SB; Lucas, WE; Markman, M, 1985)
"HMM concentrations in metastases appeared to be higher than in the primary tumor, and in metastases with a diameter less than 3 mm, drug levels were two to ten times those in larger ones."1.26Hexamethylmelamine distribution in patients with ovarian and other pelvic cancers. ( D'Incalci, M; Farina, P; Garattini, S; Mangioni, C; Sessa, C, 1982)
"Twenty-one patients with advanced ovarian cancer proven resistant to standard alkylating chemotherapy were evaluated in a prospective study of Hexamethylmelamine."1.26Hexamethylmelamine in alkylating agent-resistant ovarian carcinoma. ( Bender, RA; Chabner, BA; DeVita, VT; Fisher, RI; Johnson, BL; Young, RC, 1978)
"Epithelial ovarian cancer is usually diagnosed late in its biologic course (70% of cases are diagnosed as stage III or IV)."1.26Epithelial carcinoma of the ovary: current strategies. ( Kapp, DS; Katz, ME; Luikart, S; Schwartz, PE, 1981)
"Thirteen cases of acute nonlymphocytic leukemia occurred among 5455 patients, as compared to 0."1.26Acute leukemia after alkylating-agent therapy of ovarian cancer. ( Fraumeni, JF; Hoover, R; Reimer, RR; Young, RC, 1977)
"Its activity is most marked in ovarian cancer, lymphomas, and carcinoma of the cervix; the drug is also active in bronchogenic carcinoma and carcinoma of the breast."1.26Hexamethylmelamine. An evaluation of its role in the therapy of cancer. ( Carter, SK; Legha, SS; Slavik, M, 1976)
"Thirty-eight women with advanced ovarian cancer resistant to alkylating-agent chemotherapy were treated with a combination of hexamethylmelamine and cisplatin."1.26Hexamethylmelamine and cisplatin in advanced ovarian cancer after failure of alkylating-agent therapy. ( Arseneau, JC; Davis, TE; Einhorn, N; Kaplan, BH; Pagano, M; Tunca, JC; Vogl, SE, 1982)

Research

Studies (209)

TimeframeStudies, this research(%)All Research%
pre-1990148 (70.81)18.7374
1990's49 (23.44)18.2507
2000's12 (5.74)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Kwon, YS1
Nam, JH1
Kim, DY1
Suh, DS1
Kim, JH1
Kim, YM1
Kim, YT1
Keldsen, N1
Havsteen, H2
Vergote, I2
Bertelsen, K2
Jakobsen, A2
Wang, C1
Gu, M1
Wang, S1
Ma, D1
Chan, JK1
Loizzi, V1
Manetta, A3
Berman, ML1
Herzog, TJ1
Markman, M3
Liu, PY2
Rothenberg, ML2
Monk, BJ1
Brady, M1
Alberts, DS5
Neijt, JP11
ten Bokkel Huinink, WW11
van der Burg, ME10
van Oosterom, AT10
Vriesendorp, R2
Kooyman, CD2
van Lindert, AC4
Hamerlynck, JV2
van Lent, M3
van Houwelingen, JC2
Surwit, EA1
Crisp, W1
Jackson, RA1
Grozea, PN1
Leigh, S1
Carmo-Pereira, J2
Costa, FO2
Henriques, E2
Ricardo, JA1
Vogl, SE7
Pagano, M3
Davis, TE3
Einhorn, N2
Tunca, JC1
Kaplan, BH7
Arseneau, JC1
Honetz, N1
Pino y Torres, JL1
Bross, DS1
Hernandez, E2
Rosenshein, N1
Klein, JL1
Ettinger, DS2
Leichner, PK1
Order, SE2
Rosenshein, NB1
Villar, J1
Dillon, MB1
Brower, MS1
Coleman, M3
Pasmantier, MW3
Silver, RT3
Mamaril, AP1
Quiguyan, CC1
Davis, BW2
Goldhirsch, A4
Locher, GW1
Dreher, E4
Greiner, R4
Burki, K1
Brunner, KW3
de Gramont, A2
Krulik, M2
Pigne, A2
Brissaud, P1
Sirinelli, A1
Hubert, D1
Zylberait, D1
Debray, J1
Omura, GA2
Morrow, CP1
Blessing, JA2
Miller, A1
Buchsbaum, HJ2
Homesley, HD3
Leone, L1
Bruckner, HW8
Cohen, CJ6
Goldberg, JD2
Kabakow, B4
Wallach, RC2
Deppe, G2
Reisman, AZ1
Gusberg, SB1
Holland, JF6
Edwards, CL2
Herson, J3
Gershenson, DM1
Copeland, LJ1
Wharton, JT4
Herrmann, U1
Locher, G2
Hainsworth, JD4
Malcolm, A1
Johnson, DH3
Burnett, LS4
Jones, HW4
Greco, FA6
Greenwald, E4
Arseneau, J2
Bennett, B1
Hahn, DA1
Giannattasio, M1
Rizzi, R1
Coratelli, P1
Restaino, A1
Selvaggi, L1
Ferreri, R1
Orlando, E1
Ierardi, GM1
Granata, A1
Bettocchi, S1
Morasca, L3
Erba, E3
Vaghi, M1
Ghelardoni, C1
Mangioni, C9
Sessa, C8
Landoni, F1
Garattini, S4
Garattini, E3
Colombo, T4
Donelli, MG2
Catalani, P1
Bianchi, M1
D'Incalci, M11
Pantarotto, C2
Decker, DG1
Bruntsch, U2
Gallmeier, WM2
Piver, MS2
Barlow, JJ2
Lele, SB3
Malfetano, JH1
McPhee, ME1
ten Berge, RJ1
Schellekens, PT1
Bruning, PF1
Pinedo, HM4
Stehman, FB1
Ehrlich, CE1
Callangan, MF1
Onnis, A1
Maggino, T1
Richman, CM2
Makii, MM1
Weiser, PA2
Herbst, AL2
Calciati, A1
Clerico, M1
Donadio, M1
Giaccone, G1
Meerpohl, HG1
Broggini, M2
Coccia, P1
Rossi, C2
Kohorn, EI2
Klein-Angerer, S1
Dembo, AJ2
Ozols, RF9
Young, RC13
Thigpen, JT2
Vance, RB2
Balducci, L1
Khansur, T2
Seltzer, V2
Calanog, A1
Moukhtar, M4
Camacho, F1
Neville, AJ1
Gilchrist, KW1
Grigorova, TM1
Vartanian, LG1
Marenich, AF2
Balconi, G1
Lopez, JA1
Krikorian, JG1
Dias, SF1
Spiers, AS1
Finkel, HE1
Barnard, DE1
Katz, ME1
Schwartz, PE2
Kapp, DS1
Luikart, S1
Julian, CG1
Richardson, RL1
Burnett, L1
Hande, KR1
Oldham, RK1
Paesani, R1
De Palo, G1
Demicheli, R1
Valagussa, P1
De Lena, M1
Villa, E1
Weiss, RB1
Wallach, R2
Ratner, L1
Farina, P2
Beggiolin, G1
Valente, I2
Bolis, G6
Colombo, N4
Razis, DV1
Poulakou, E1
Petounis, A1
Papadimitriou, G1
Kosmides, P1
Delides, G1
Myers, CE2
Hogan, WM1
Fuks, Z3
Rizel, S3
Anteby, SO4
Biran, S3
Griffith, AB1
Tempero, MA1
Kessinger, A1
Lund, B2
Aabo, K1
Rørth, M1
Hansen, HH2
Madonna, R1
Lee, CR2
Faulds, D1
Mäenpää, JU1
Heinonen, E2
Hinkka, SM1
Karnani, P1
Klemi, PJ1
Korpijaakko, TA1
Kuoppala, TA1
Laine, AM1
Lähde, MA1
Nuoranne, EK1
Frasci, G1
Comella, G1
Comella, P1
Conforti, S1
Mastrantonio, P1
Zullo, F1
Persico, G1
Barker, IK1
Crawford, SM1
Fell, AF1
Moore, DH2
Valea, F1
Crumpler, LS2
Fowler, WC2
Levin, L2
Simon, R3
Hryniuk, W2
McGuire, WP1
Dorval, T1
Beuzeboc, P1
Garcia-Giralt, E1
Jouve, M1
Livartowski, A1
Palangie, T1
Pouillart, P1
Kristensen, GB1
Baekelandt, M1
Vergote, IB1
Tropé, C2
Wadler, S1
Yeap, B2
Vogl, S2
Carbone, P1
Nicholson, PW1
Ledermann, JA1
Rustin, GJ2
Nishimura, H1
Imamura, K1
Chang, C1
Edelman, DZ1
Peretz, T1
Nelstrop, AE1
Crawford, M1
Ledermann, J1
Lambert, HE1
Coleman, R1
Johnson, J1
Evans, H1
Brown, S1
Oster, W1
Moore, D1
Ball, H1
Lentz, SS1
Lotz, JP1
Lhommé, C1
Pautier, P1
Couteau, C1
Gligorov, J1
Alexandre, J1
Selle, F1
Izrael, V1
Maraninchi, D1
Viens, P1
Gershanovich, ML2
Livshits, ME2
Makhnova, EV1
Antipenkova, VI1
Sørensen, P1
Høyer, M1
Malmström, H1
Wilczynski, S1
Hannigan, EV1
Weiner, SA1
Weiss, GR1
Hunter, VJ1
Chapman, JA1
Tiersten, A1
Kohler, PC1
Olver, I1
Davy, M1
Lüftner, D1
Park, SH1
Egorin, M1
Ellis, A1
Webster, L1
Chabner, BA3
Hubbard, SP2
Fisher, RI4
Bender, RA2
Anderson, T1
Simon, RM2
Canellos, GP2
DeVita, VT3
Johnson, BL1
Bonomi, PD1
Mladineo, J1
Morrin, B1
Wilbanks, G1
Slayton, RE1
Wollner, D1
Vendrik, CP1
Roozendaal, KJ1
Struyvenberg, A1
Garvin, AJ1
Costa, J1
Hilgers, RD2
Moon, TE1
Martimbeau, PW1
Rivkin, S1
Kane, R1
Harvey, H1
Andrews, T1
Bernath, A1
Curry, S1
Dixon, R1
Gottlieb, R1
Kukrika, M1
Lipton, A1
Mortel, R1
Ricci, J1
White, D1
Berenzweig, M1
Bulkin, W1
Belloni, C2
Byrd, R1
Malpas, JS1
Rutledge, F2
Smith, JP4
Hodge, MP1
Stanhope, CR1
Reimer, RR1
Hoover, R1
Fraumeni, JF1
Lewis, GC1
Blessing, J1
Kardinal, CG1
Luce, JK1
Barber, HR1
Kwon, T1
Buterman, I1
Kakarla, R1
Legha, SS1
Slavik, M1
Carter, SK1
Rutledge, FN2
Dalesio, O3
Rodenhuis, S1
Dubbelman, R1
Hilton, A1
Franklin, H1
Koier, I1
van Tinteren, H1
Muggia, F1
Norris, K1
Himmelmann, A1
Frankendal, B1
Scheistrøen, M1
Vlachos, K1
Hauge, MD1
Long, HJ1
Hartmann, LC1
Edmonson, JH3
Webb, MJ1
Su, J1
Wiernik, PH1
Comis, RL1
Falkson, G1
Fazzini, E1
Cheuvart, B1
Horton, J1
Pinon, G1
Pinel, MC1
Goudier, MJ1
Coiffier, B1
Filippi, MH1
Goupil, A1
Roullet, B1
Facchini, T1
Mignot, L1
Tresca, P1
Willemse, PH2
Vermorken, JB3
Heintz, AP4
Aartsen, E1
Venesmaa, P1
Ylikorkala, O1
MacNeill, C2
Lyter, JA2
Scheffler, B3
Podczaski, ES2
Larson, JE2
Schein, P2
Marsoni, S3
Cohen, C1
Mandeli, J1
Chesser, MR2
Holland, J1
Schein, PS2
McCulloch, W1
Brady, MF1
Yordan, E1
Major, FJ1
Park, RC1
Hansen, LA1
Hughes, TE1
Gorbunova, VA1
Perevodchikova, NI1
Kozachenko, VP1
Ryzhakov, VM1
Zhordania, KI1
Jones, CP1
Wils, JA1
Cohen, MH1
Korn, EL1
Torri, V1
Valsecchi, MG1
Bianchi, U1
Bonazzi, C1
Epis, A1
Favalli, G1
van der Hoop, RG1
van Houwelingen, C1
Hansen, M1
Thomsen, HK1
Sørensen, BL1
Nielsen, NC1
Lundvall, F1
Boogerd, W1
Hoppenbrouwers, WJ1
van der Sande, JJ1
Inoue, K1
Patsner, B1
Tsukada, Y1
Bielat, K1
Castillo, NB1
Leonard, RC1
Smart, GE1
Livingstone, JR1
Cornbleet, MA1
Kerr, GR1
Fletcher, S1
Webb, JN1
Smyth, JF1
Feuer, E3
Sipilä, P1
Kivinen, S1
Gröhn, P1
Vesala, J1
Scarantino, CW1
Muss, HB1
Welander, CE1
Bhardwaj, S1
Ang, PT1
Kavanagh, J1
Griffin, TW1
Hunter, RA1
Cederbaum, AI1
Tak, WK1
Ward, AD1
Schwartz, JH1
Halpin, TF1
Strauss, GM1
Meyer, RN1
Liepman, MK1
Brufman, G1
Sulkes, A1
Milwidsky, A1
Weshler, Z1
Grosh, WW2
Podczaski, E1
Abrams, J1
Belinson, JL1
Pretorius, RG1
McClure, M1
Ashikaga, T1
Drolet, Y1
Louvet, C1
Dray, C1
Lavoie, A1
Painchaud, M1
Blouin, R1
Tessier, C1
Tanke, HJ1
van Vianen, PH1
Emiliani, FM1
Neuteboom, I1
de Vogel, N1
Tates, AD1
de Bruijn, EA1
Foster, BJ1
Clagett-Carr, K1
Leyland-Jones, B1
Laufman, LR1
Green, JB1
O'Toole, R1
Young, DC1
Lin, F1
Rivkin, SE1
Louie, KG1
Ostchega, Y1
Jenkins, J1
Howser, D1
Keating, G1
Chambers, JT1
Boven, E1
Nauta, MM1
Schlüper, HM1
Erkelens, CA1
Grubb, BP1
Thant, M1
Simon, A1
Fields, S1
Schenker, JG1
Pater, JL1
Carmichael, JA2
Krepart, GV1
Fraser, RC1
Roy, M1
Kirk, ME1
Levitt, M1
Brown, LB1
Wilson, KS1
Shelley, WE2
Rosen, GF1
Lurain, JR1
Newton, M1
Wu, BZ1
Reed, E1
Tarone, R1
Yuspa, SH1
Poirier, MC1
Lichter, AS1
Myers, CC1
Ostechega, Y1
Trimbos, JB3
Bouma, J1
Jansen, RL1
Verweij, J1
Stoter, G1
Wolff, SN1
Neef, C1
de Voogd-van der Straaten, I1
Krauer, F1
Forni, M1
Jungi, FW1
Veraguth, P1
Engeler, V1
Zanaboni, F1
Aalders, JG1
Ross, WM1
Schaberg, A1
Van der Velde, EA1
Nooy, M1
George, M1
Guastalla, JP1
Veenhof, CH1
Rotmensz, N1
Wieand, HS1
McCormack, GW2
Posada, JG1
Marantz, AB1
Yeung, KY1
Smith, FP2
Delgado, G2
Edwards, BK1
Kaplan, B1
McLaughlin, EK1
Tuholski, N1
Mermillod, B1
Lucas, WE1
Howell, SB1
Ballard, WP1
Fuller, AF1
Krane, IM1
Budzik, GP1
Donahoe, PK1
Carlson, JA1
Day, TG1
Botts, B1
Masterson, BJ1
Mäenpää, J1
Kangas, L1
Grönroos, M1
Fleming, TR1
Cullinan, SA1
Krook, JE1
Malkasian, GD1
Podratz, KC1
Mailliard, JA1
Jefferies, JA1
Barlow, JF1
Reinhard, JP1
Joss, R1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase III Randomized Trial of 12 Months vs. 3 Months of Paclitaxel in Patients With Advanced Ovarian Cancer Who Attain a Clinically Defined Complete Response (CR) Following Platinum/Paclitaxel-Based Chemotherapy[NCT00003120]Phase 3308 participants (Actual)Interventional1997-11-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

25 reviews available for altretamine and Cancer of Ovary

ArticleYear
Recurrent ovarian cancer: how important is it to treat to disease progression?
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Nov-15, Volume: 10, Issue:22

    Topics: Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cis

2004
[Progress in the chemotherapy of ovarian cancer].
    Wiener medizinische Wochenschrift (1946), 1982, Jul-31, Volume: 132, Issue:13-14

    Topics: Adenocarcinoma, Mucinous; Altretamine; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; C

1982
[Chemotherapy of advanced epithelial ovarian carcinoma].
    Onkologie, 1984, Volume: 7 Suppl 2

    Topics: Alkylating Agents; Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocol

1984
Radiotherapeutic management of ovarian cancer.
    Seminars in oncology, 1984, Volume: 11, Issue:3

    Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Co

1984
Chemotherapy of ovarian cancer.
    Seminars in oncology, 1984, Volume: 11, Issue:3

    Topics: Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclo

1984
New drugs and experimental approaches in ovarian cancer treatment.
    Seminars in oncology, 1984, Volume: 11, Issue:3

    Topics: Altretamine; Aminoacridines; Amsacrine; Antineoplastic Agents; Aziridines; Benzoquinones; Busulfan;

1984
The role of hexamethylmelamine in advanced ovarian carcinoma treatment.
    Gynecologic oncology, 1981, Volume: 12, Issue:2 Pt 1

    Topics: Altretamine; Drug Therapy, Combination; Female; Humans; Nervous System Diseases; Ovarian Neoplasms;

1981
Altretamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cancer chemotherapy.
    Drugs, 1995, Volume: 49, Issue:6

    Topics: Altretamine; Antineoplastic Agents; Female; Humans; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Sa

1995
Advances in the chemotherapy of gynecologic cancer.
    Current opinion in oncology, 1994, Volume: 6, Issue:5

    Topics: Altretamine; Antineoplastic Agents; Clinical Trials as Topic; Endometrial Neoplasms; Etoposide; Fema

1994
Second-line chemotherapy for recurrent carcinoma of the ovary.
    Cancer, 1993, Feb-15, Volume: 71, Issue:4 Suppl

    Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Resistance; Female; Hum

1993
Primary treatment of epithelial ovarian malignancies.
    Cancer, 1993, Feb-15, Volume: 71, Issue:4 Suppl

    Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisp

1993
[Chemotherapy for recurrent ovarian cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1996, Volume: 23, Issue:9

    Topics: Adenocarcinoma, Clear Cell; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin

1996
[Chemotherapy for recurrent or advanced persistent epithelial ovarian cancer].
    Harefuah, 1996, Volume: 131, Issue:1-2

    Topics: Altretamine; Antineoplastic Agents; Cisplatin; Etoposide; Female; Humans; Ifosfamide; Ovarian Neopla

1996
[High-dose chemotherapy in ovarian adenocarcinoma].
    Bulletin du cancer, 2000, Volume: 87, Issue:1

    Topics: Adenocarcinoma; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophospha

2000
Chemotherapy in the management of ovarian carcinoma: a review.
    Journal of the Royal Society of Medicine, 1979, Volume: 72, Issue:5

    Topics: Alkylating Agents; Altretamine; Antineoplastic Agents; Cisplatin; Doxorubicin; Drug Therapy, Combina

1979
Chemotherapy of ovarian cancer.
    The Surgical clinics of North America, 1978, Volume: 58, Issue:1

    Topics: Alkylating Agents; Altretamine; Cisplatin; Doxorubicin; Drug Therapy, Combination; Female; Fluoroura

1978
Chemotherapy of ovarian cancer: past and present.
    Seminars in oncology, 1975, Volume: 2, Issue:3

    Topics: Acrylates; Alkylating Agents; Altretamine; Antineoplastic Agents; Cyclophosphamide; Dactinomycin; Do

1975
Role of chemotherapy in the future treatment of ovarian cancer.
    Acta obstetricia et gynecologica Scandinavica. Supplement, 1992, Volume: 155

    Topics: Alkaloids; Altretamine; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Prot

1992
Hexamethylmelamine (altretamine): early National Cancer Institute trials.
    Cancer treatment reviews, 1991, Volume: 18 Suppl A

    Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophospham

1991
The role of hexamethylmelamine in the management of ovarian cancer.
    Cancer treatment reviews, 1991, Volume: 18 Suppl A

    Topics: Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-U

1991
Ovarian cancer: new clinical approaches.
    Cancer treatment reviews, 1991, Volume: 18 Suppl A

    Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Ovarian Neoplasms; Recu

1991
Altretamine.
    DICP : the annals of pharmacotherapy, 1991, Volume: 25, Issue:2

    Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Cy

1991
Role of hexamethylmelamine in the treatment of ovarian cancer: where is the needle in the haystack?
    Cancer treatment reports, 1986, Volume: 70, Issue:8

    Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Administ

1986
Current status of chemotherapy for ovarian carcinoma.
    European journal of cancer & clinical oncology, 1988, Volume: 24, Issue:4

    Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubici

1988
The sequential multiple modality treatment of ovarian cancer.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 1985, Volume: 3, Issue:3

    Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; C

1985

Trials

67 trials available for altretamine and Cancer of Ovary

ArticleYear
Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a phase II study.
    Gynecologic oncology, 2003, Volume: 88, Issue:2

    Topics: Administration, Oral; Aged; Altretamine; Antineoplastic Agents, Alkylating; Drug Resistance, Neoplas

2003
Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs CHAP-5) in advanced ovarian carcinoma.
    Lancet (London, England), 1984, Sep-15, Volume: 2, Issue:8403

    Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Cy

1984
Advanced ovarian carcinoma: a prospective and randomized clinical trial of cyclophosphamide versus combination cytotoxic chemotherapy (Hexa-CAF).
    Cancer, 1981, Nov-01, Volume: 48, Issue:9

    Topics: Adenocarcinoma, Mucinous; Adult; Aged; Altretamine; Antineoplastic Agents; Carcinoma; Clinical Trial

1981
Multimodality treatment of patients with advanced ovarian carcinoma.
    International journal of radiation oncology, biology, physics, 1982, Volume: 8, Issue:10

    Topics: Adenocarcinoma, Mucinous; Altretamine; Antibodies, Neoplasm; Carcinoma; Cisplatin; Clinical Trials a

1982
A randomized comparison of melphalan versus melphalan plus hexamethylmelamine versus adriamycin plus cyclophosphamide in ovarian carcinoma.
    Cancer, 1983, Mar-01, Volume: 51, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Altretamine; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; D

1983
Cisplatin regimens and improved prognosis of patients with poorly differentiated ovarian cancer.
    American journal of obstetrics and gynecology, 1983, Mar-15, Volume: 145, Issue:6

    Topics: Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclo

1983
cis-Platinum, adriamycin, and hexamethylmelamine versus cyclophosphamide in advanced ovarian carcinoma.
    Cancer chemotherapy and pharmacology, 1983, Volume: 10, Issue:2

    Topics: Adult; Aged; Altretamine; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Femal

1983
A prospective randomized clinical trial of melphalan and cis-platinum versus hexamethylmelamine, adriamycin, and cyclophosphamide in advanced ovarian cancer.
    Gynecologic oncology, 1983, Volume: 15, Issue:2

    Topics: Adult; Altretamine; Anemia; Antineoplastic Agents; Cisplatin; Clinical Trials as Topic; Cyclophospha

1983
Improved therapy with cisplatin regimens for patients with ovarian carcinoma (FIGO III and IV) as measured by surgical end-staging (second-look surgery)--the mount sinai experience.
    Clinics in obstetrics and gynaecology, 1983, Volume: 10, Issue:2

    Topics: Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clini

1983
Mayo Clinic experience with epithelial ovarian cancer.
    Clinics in obstetrics and gynaecology, 1983, Volume: 10, Issue:2

    Topics: Adenocarcinoma; Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols;

1983
Combination chemotherapy and immune capacity in advanced ovarian carcinoma.
    European journal of cancer & clinical oncology, 1984, Volume: 20, Issue:1

    Topics: Adult; Aged; Altretamine; Antibody Formation; Antineoplastic Combined Chemotherapy Protocols; Cispla

1984
Radiotherapeutic management of ovarian cancer.
    Seminars in oncology, 1984, Volume: 11, Issue:3

    Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Co

1984
Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma.
    Cancer treatment reports, 1984, Volume: 68, Issue:12

    Topics: Adenocarcinoma; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Tri

1984
Medical Research Council study on chemotherapy in advanced ovarian cancer. Medical Research Council's Working Party on ovarian cancer.
    British journal of obstetrics and gynaecology, 1981, Volume: 88, Issue:12

    Topics: Aged; Altretamine; Clinical Trials as Topic; Cyclophosphamide; Female; Humans; Methotrexate; Middle

1981
Single-agent adriamycin followed by combination hexamethylmelamine-cyclophosphamide for advanced ovarian carcinoma.
    Gynecologic oncology, 1982, Volume: 14, Issue:2

    Topics: Adult; Altretamine; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Therapy, Combinati

1982
The subrenal capsule assay in selecting chemotherapy for ovarian cancer: a prospective randomized trial.
    Gynecologic oncology, 1995, Volume: 57, Issue:3

    Topics: Aged; Altretamine; Animals; Antineoplastic Combined Chemotherapy Protocols; Carbazilquinone; Carbopl

1995
Carboplatin (CBDCA)-hexamethylmelamine (HMM)-oral etoposide (VP-16) first-line treatment of ovarian cancer patients with bulky disease: a phase II study.
    Gynecologic oncology, 1995, Volume: 58, Issue:1

    Topics: Administration, Oral; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin

1995
[Treatment of cancers of the ovary. Phase II trial of increase of the dose of cisplatin].
    Presse medicale (Paris, France : 1983), 1993, Jan-30, Volume: 22, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin;

1993
A phase II study of carboplatin and hexamethylmelamine as induction chemotherapy in advanced epithelial ovarian carcinoma.
    European journal of cancer (Oxford, England : 1990), 1995, Volume: 31A, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carbopl

1995
Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Cancer, 1996, Feb-15, Volume: 77, Issue:4

    Topics: Adult; Aged; Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Car

1996
Patient compliance with prolonged oral altretamine treatment in relapsed ovarian cancer.
    European journal of gynaecological oncology, 1996, Volume: 17, Issue:2

    Topics: Administration, Oral; Aged; Altretamine; Antineoplastic Agents, Alkylating; Female; Humans; Middle A

1996
Phase II trial of oral altretamine for relapsed ovarian carcinoma: evaluation of defining response by serum CA125.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1997, Volume: 15, Issue:1

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Altretamine; Antineoplastic Agents, Alkylating

1997
Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial.
    Gynecologic oncology, 1998, Volume: 69, Issue:3

    Topics: Administration, Oral; Adult; Aged; Altretamine; Antineoplastic Agents, Alkylating; Drug Resistance,

1998
Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma.
    Gynecologic oncology, 2001, Volume: 81, Issue:1

    Topics: Adult; Aged; Altretamine; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Pr

2001
Phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer: a Southwest Oncology Group trial (SWOG-9326).
    Gynecologic oncology, 2001, Volume: 82, Issue:2

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Altretamine; Antineoplastic Agents, Alkylating

2001
A phase I study of paclitaxel and altretamine as second-line therapy to cisplatin regimens for ovarian cancer.
    Cancer chemotherapy and pharmacology, 2001, Volume: 48, Issue:2

    Topics: Administration, Oral; Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisp

2001
Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy.
    The New England journal of medicine, 1978, Dec-07, Volume: 299, Issue:23

    Topics: Adenocarcinoma; Adult; Aged; Altretamine; Antineoplastic Agents; Cyclophosphamide; Drug Administrati

1978
Phase II trial of hexamethylmelamine in ovarian carcinoma resistant to alkylating agents.
    Cancer treatment reports, 1979, Volume: 63, Issue:1

    Topics: Alkylating Agents; Altretamine; Clinical Trials as Topic; Drug Evaluation; Drug Resistance; Female;

1979
Hexa-CAF combination chemotherapy and other multiple-drug regimens in advanced ovarian carcinoma: present and future.
    The Netherlands journal of medicine, 1979, Volume: 22, Issue:2

    Topics: Altretamine; Cisplatin; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Therapy, Combi

1979
Histologic grade in advanced ovarian cancer.
    Cancer treatment reports, 1979, Volume: 63, Issue:2

    Topics: Altretamine; Cell Differentiation; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil

1979
Hexamethylmelamine in ovarian cancer resistant to cyclophosphamide and adriamycin.
    Cancer treatment reports, 1979, Volume: 63, Issue:8

    Topics: Adult; Aged; Altretamine; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Drug Resistan

1979
Advances in the staging and treatment of ovarian cancer.
    Cancer, 1977, Volume: 39, Issue:2 Suppl

    Topics: Alkylating Agents; Altretamine; Antimetabolites, Antineoplastic; Clinical Trials as Topic; Cyclophos

1977
Second trial drugs in ovarian cancer.
    Gynecologic oncology, 1977, Volume: 5, Issue:1

    Topics: Altretamine; Cyclophosphamide; Dactinomycin; Doxorubicin; Drug Therapy, Combination; Female; Fluorou

1977
Ovarian cancer: use of multiple modality programs involving surgery, radiation therapy and chemotherapy.
    Cancer, 1977, Volume: 40, Issue:1 Suppl

    Topics: Altretamine; Antineoplastic Agents; Clinical Trials as Topic; Cyclophosphamide; Dactinomycin; Doxoru

1977
Evaluation of a hexamethylmelamine and 5-fluorouracil combination in the treatment of advanced ovarian carcinoma.
    Cancer treatment reports, 1977, Volume: 61, Issue:9

    Topics: Altretamine; Bone Marrow; Clinical Trials as Topic; Digestive System; Drug Evaluation; Drug Therapy,

1977
Preliminary Results of trials of chemotherapy in advanced ovarian carcinoma.
    National Cancer Institute monograph, 1975, Volume: 42

    Topics: Altretamine; Antineoplastic Agents; Clinical Trials as Topic; Cyclophosphamide; Drug Therapy, Combin

1975
Random study of hexamethylmelamine, 5-fluorouracil, and melphalan in treatment of advanced carcinoma of the ovary.
    National Cancer Institute monograph, 1975, Volume: 42

    Topics: Adult; Altretamine; Antineoplastic Agents; Drug Therapy, Combination; Female; Fluorouracil; Humans;

1975
Replacement of cisplatin with carboplatin in combination chemotherapy against ovarian cancer: long-term treatment results of a study of the Gynaecological Cancer Cooperative Group of the EORTC and experience at The Netherlands Cancer Institute.
    Seminars in oncology, 1992, Volume: 19, Issue:1 Suppl 2

    Topics: Adult; Aged; Aged, 80 and over; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carbopl

1992
Phase II trial of intravenous hexamethylmelamine in patients with advanced ovarian cancer.
    Investigational new drugs, 1992, Volume: 10, Issue:4

    Topics: Altretamine; Female; Humans; Infusions, Intravenous; Ovarian Neoplasms

1992
Hexamethylmelamine and low or moderate dose cisplatin with or without pyridoxine for treatment of advanced ovarian carcinoma: a study of the Eastern Cooperative Oncology Group.
    Cancer investigation, 1992, Volume: 10, Issue:1

    Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule

1992
Long-term survival in ovarian cancer. Mature data from The Netherlands Joint Study Group for Ovarian Cancer.
    European journal of cancer (Oxford, England : 1990), 1991, Volume: 27, Issue:11

    Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubici

1991
Subrenal capsule assay in selection of chemotherapy after operation for recurrent ovarian cancer.
    British journal of cancer, 1991, Volume: 63, Issue:1

    Topics: Adult; Aged; Altretamine; Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclop

1991
Hexamethylmelamine (altretamine): early National Cancer Institute trials.
    Cancer treatment reviews, 1991, Volume: 18 Suppl A

    Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophospham

1991
Randomized comparison of hexamethylmelamine, adriamycin, cyclophosphamide (HAC) vs. cisplatin, adriamycin, cyclophosphamide (PAC) in advanced ovarian cancer: long-term results.
    Cancer treatment reviews, 1991, Volume: 18 Suppl A

    Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubici

1991
A comparison of hexamethylmelamine (altretamine), cyclophosphamide, doxorubicin, and cisplatin (H-CAP) vs. cyclophosphamide, doxorubicin, and cisplatin (CAP) in advanced ovarian cancer.
    Cancer treatment reviews, 1991, Volume: 18 Suppl A

    Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubici

1991
Hexamethylmelamine for the treatment of ovarian cancer--the Mount Sinai experience.
    Cancer treatment reviews, 1991, Volume: 18 Suppl A

    Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dose-Respo

1991
Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1991, Volume: 9, Issue:7

    Topics: Adult; Aged; Altretamine; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Carc

1991
Hexamethylmelamine chemotherapy for persistent or recurrent epithelial ovarian cancer.
    American journal of obstetrics and gynecology, 1991, Volume: 165, Issue:3

    Topics: Adult; Aged; Altretamine; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms

1991
Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin.
    Cancer, 1990, Oct-15, Volume: 66, Issue:8

    Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubici

1990
A randomized study of sequential versus alternating combination chemotherapy in advanced ovarian carcinoma.
    Annals of oncology : official journal of the European Society for Medical Oncology, 1990, Volume: 1, Issue:2

    Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cycl

1990
Randomised trial comparing prednimustine with combination chemotherapy in advanced ovarian carcinoma.
    Cancer chemotherapy and pharmacology, 1989, Volume: 23, Issue:2

    Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cisplatin; Clinical Trial

1989
Concurrent chemotherapy and single high-dose plus whole abdominopelvic radiation for persistent ovarian carcinoma.
    Gynecologic oncology, 1989, Volume: 34, Issue:2

    Topics: Abdomen; Altretamine; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Female; Humans

1989
Complete remission at laparotomy: still a gold standard in ovarian cancer?
    Lancet (London, England), 1986, May-03, Volume: 1, Issue:8488

    Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Co

1986
Present optimal therapy in ovarian cancer.
    European journal of cancer & clinical oncology, 1986, Volume: 22, Issue:1

    Topics: Alkylating Agents; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical

1986
Role of hexamethylmelamine in the treatment of ovarian cancer: where is the needle in the haystack?
    Cancer treatment reports, 1986, Volume: 70, Issue:8

    Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Administ

1986
Chemotherapy of drug-resistant ovarian cancer: a Southwest Oncology Group Study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1986, Volume: 4, Issue:9

    Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Clin

1986
Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1986, Volume: 4, Issue:11

    Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamid

1986
CHAP II therapy for epithelial ovarian cancers following primary treatment with platinum-based combination chemotherapy.
    Gynecologic oncology, 1986, Volume: 25, Issue:3

    Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Clin

1986
Second-line chemotherapy of stage III-IV ovarian carcinoma: a randomized comparison of melphalan to melphalan and hexamethylmelamine in patients with persistent disease after doxorubicin and cisplatin.
    Cancer treatment reports, 1987, Volume: 71, Issue:3

    Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials

1987
"Role of hexamethylmelamine in the treatment of ovarian cancer: where is the needle in the haystack?".
    Cancer treatment reports, 1987, Volume: 71, Issue:6

    Topics: Altretamine; Clinical Trials as Topic; Female; Humans; Ovarian Neoplasms; Prognosis; Triazines

1987
Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1987, Volume: 5, Issue:8

    Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carcinoma; Cispla

1987
The application of dose intensity to problems in chemotherapy of ovarian and endometrial cancer.
    Seminars in oncology, 1987, Volume: 14, Issue:4 Suppl 4

    Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Cy

1987
Treatment of advanced ovarian cancer with surgery, chemotherapy, and consolidation of response by whole-abdominal radiotherapy.
    Cancer, 1988, Jul-01, Volume: 62, Issue:1

    Topics: Abdomen; Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinic

1988
Carboplatin in combination therapy for ovarian cancer.
    Cancer treatment reviews, 1988, Volume: 15 Suppl B

    Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cl

1988
Hexamethylmelamine, adriamycin, and cyclophosphamide (HAC) versus cis-dichlorodiamineplatinum, adriamycin, and cyclophosphamide (PAC) in advanced ovarian cancer: a randomized clinical trial.
    Cancer chemotherapy and pharmacology, 1985, Volume: 14, Issue:3

    Topics: Adolescent; Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cli

1985
The case for combination chemotherapy in the treatment of advanced ovarian cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1985, Volume: 3, Issue:11

    Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Cy

1985
Comparison of cyclophosphamide plus cisplatin versus hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin in combination as initial chemotherapy for stage III and IV ovarian carcinomas.
    Cancer treatment reports, 1985, Volume: 69, Issue:11

    Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials

1985

Other Studies

120 other studies available for altretamine and Cancer of Ovary

ArticleYear
Hexamethylmelamine as consolidation treatment for patients with advanced epithelial ovarian cancer in complete response after first-line chemotherapy.
    Journal of Korean medical science, 2009, Volume: 24, Issue:4

    Topics: Altretamine; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Dise

2009
Comparative study on three chemotherapeutic regimens for the treatment of advanced epithelial ovarian cancer.
    Journal of Tongji Medical University = Tong ji yi ke da xue xue bao, 2000, Volume: 20, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplat

2000
Oral altretamine used as salvage therapy in recurrent ovarian cancer.
    Gynecologic oncology, 2004, Volume: 92, Issue:1

    Topics: Administration, Oral; Aged; Altretamine; Antineoplastic Agents, Alkylating; Female; Humans; Middle A

2004
Pretreatment CA-125 and risk of relapse in advanced ovarian cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2006, Mar-20, Volume: 24, Issue:9

    Topics: Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Disease Progressi

2006
Multiagent chemotherapy in relapsing ovarian cancer.
    American journal of obstetrics and gynecology, 1983, Jul-15, Volume: 146, Issue:6

    Topics: Altretamine; Bleomycin; Cisplatin; Clone Cells; Drug Therapy, Combination; Female; Humans; Neoplasm

1983
Hexamethylmelamine and cisplatin in advanced ovarian cancer after failure of alkylating-agent therapy.
    Cancer treatment reports, 1982, Volume: 66, Issue:6

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Altretamine; Cisplatin; Cystadenocarcinoma; D

1982
Alternating multiagent chemotherapy for advanced ovarian cancer.
    Journal of surgical oncology, 1983, Volume: 22, Issue:2

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Altretamine; Antineoplastic Agents; Cisplatin; Cyclophosph

1983
Treatment of advanced ovarian carcinoma with hexamethylmelamine, doxorubicin, and cis-platinum (HAC): results in both untreated and previously treated patients.
    Medical and pediatric oncology, 1984, Volume: 12, Issue:1

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Altretamine; Antineoplastic Combined Chemotherapy Protocol

1984
Pathologic data of prognostic significance for remission induction in advanced ovarian carcinoma.
    Journal of cancer research and clinical oncology, 1984, Volume: 107, Issue:2

    Topics: Adenocarcinoma; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluat

1984
[Treatment of advanced ovarian cancer].
    La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris, 1984, Mar-29, Volume: 60, Issue:14

    Topics: Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxo

1984
[New therapeutic concept for advanced ovarian cancer (FIGO IIb+c, III, IV)].
    Gynakologische Rundschau, 1983, Volume: 22 Suppl 3

    Topics: Adult; Aged; Altretamine; Cisplatin; Female; Humans; Melphalan; Middle Aged; Neoplasm Staging; Ovari

1983
Advanced minimal residual ovarian carcinoma: abdominopelvic irradiation following combination chemotherapy.
    Obstetrics and gynecology, 1983, Volume: 61, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherap

1983
Cis-platin based combination chemotherapy for advanced ovarian cancer. High overall response rate with curative potential only in women with small tumor burdens.
    Cancer, 1983, Jun-01, Volume: 51, Issue:11

    Topics: Adult; Aged; Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cis

1983
Hexamethylmelamine and pentamethylmelamine: an update.
    Drug intelligence & clinical pharmacy, 1983, Volume: 17, Issue:6

    Topics: Altretamine; Antineoplastic Agents; Drug Therapy, Combination; Female; Humans; Leukemia; Lung Neopla

1983
Use of cis-platinum in the treatment of ovarian carcinoma. Clinical results and evaluation of nephrotoxicity.
    European journal of gynaecological oncology, 1983, Volume: 4, Issue:1

    Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubici

1983
Clinical correlates of in vitro drug sensitivities of ovarian cancer cells.
    British journal of cancer, 1983, Volume: 48, Issue:1

    Topics: Adult; Aged; Altretamine; Antineoplastic Agents; Cell Survival; Cells, Cultured; Cisplatin; Cyclopho

1983
Distribution, metabolism, and irreversible binding of hexamethylmelamine in mice bearing ovarian carcinoma.
    Cancer chemotherapy and pharmacology, 1983, Volume: 11, Issue:1

    Topics: Altretamine; Animals; Antineoplastic Agents; Female; Mice; Mice, Inbred C57BL; Ovarian Neoplasms; Ti

1983
[Chemotherapy of epithelial ovarian carcinoma].
    MMW, Munchener medizinische Wochenschrift, 1983, Nov-04, Volume: 125, Issue:44

    Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chlorambucil; Cisplatin; Cyc

1983
Cis-diamminedichloroplatinum (II): second line induction chemotherapy in advanced ovarian adenocarcinoma.
    Journal of surgical oncology, 1983, Volume: 24, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin;

1983
Combination chemotherapy with or without hexamethylmelamine in alkylating-agent resistant ovarian carcinoma.
    Cancer, 1984, Apr-01, Volume: 53, Issue:7

    Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Female; Humans;

1984
Failure of hexamethylmelamine as salvage therapy in ovarian epithelial adenocarcinoma resistant to combination chemotherapy.
    Gynecologic oncology, 1984, Volume: 17, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin;

1984
Repetitive debulking surgery as adjuvant to chemotherapy in advanced epithelial ovarian cancer.
    Clinical and experimental obstetrics & gynecology, 1984, Volume: 11, Issue:1-2

    Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; C

1984
The effect of lithium carbonate on chemotherapy-induced neutropenia and thrombocytopenia.
    American journal of hematology, 1984, Volume: 16, Issue:4

    Topics: Agranulocytosis; Altretamine; Cisplatin; Colony-Stimulating Factors; Cyclophosphamide; Doxorubicin;

1984
[Chemotherapy in advanced forms of carcinoma of the ovary].
    Minerva ginecologica, 1984, Volume: 36, Issue:4

    Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubici

1984
Biochemical studies on the ability of pentamethylmelamine to interact in vivo with DNA and proteins in a sensitive murine ovarian reticular cell sarcoma.
    Biochemical pharmacology, 1984, Sep-01, Volume: 33, Issue:17

    Topics: Altretamine; Animals; Antineoplastic Agents; DNA, Neoplasm; Female; Liver; Lymphoma, Large B-Cell, D

1984
The effect of chemotherapy on lymphocyte subpopulations and cell-mediated cytotoxicity in patients with ovarian carcinoma.
    Gynecologic oncology, 1984, Volume: 19, Issue:1

    Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; B-Lymphocytes; Cyclophosphamide; Cytoto

1984
"Second-effort" surgical resection for bulky ovarian cancer.
    Cancer, 1984, Nov-15, Volume: 54, Issue:10

    Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modali

1984
The chemotherapy of granulosa cell tumors of the ovary: experience of the Wisconsin Clinical Cancer Center.
    Medical and pediatric oncology, 1984, Volume: 12, Issue:6

    Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Cyclophospha

1984
Current status of systemic chemotherapy in the treatment of advanced ovarian cancer with emphasis on CHAP-5.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 1984, Volume: 2, Issue:1

    Topics: Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclo

1984
[Surgical method and combination chemotherapy in treating stage-III and IV ovarian cancer].
    Voprosy onkologii, 1980, Volume: 26, Issue:2

    Topics: Altretamine; Antineoplastic Agents; Carcinoma; Cyclophosphamide; Drug Therapy, Combination; Evaluati

1980
Time dependence of the in vitro cytotoxicity of hexamethylmelamine and its metabolites.
    British journal of cancer, 1980, Volume: 41, Issue:4

    Topics: Altretamine; Cell Line; Cells; Female; Humans; Ovarian Neoplasms; Thymidine; Time Factors; Triazines

1980
Combination chemotherapy of advanced ovarian cancer with hexamethylmelamine, cis-Platinum, and doxorubicin after failure of prior therapy.
    Obstetrics and gynecology, 1980, Volume: 56, Issue:5

    Topics: Adult; Aged; Altretamine; Antineoplastic Agents; Cisplatin; Doxorubicin; Drug Therapy, Combination;

1980
cis-Platinum-hexamethylmelamine therapy of advanced ovarian cancer.
    Gynecologic oncology, 1981, Volume: 11, Issue:1

    Topics: Adult; Altretamine; Cisplatin; Drug Therapy, Combination; Female; Humans; Middle Aged; Nausea; Ovari

1981
Epithelial carcinoma of the ovary: current strategies.
    Annals of internal medicine, 1981, Volume: 95, Issue:1

    Topics: Alkylating Agents; Altretamine; Antineoplastic Agents; Carcinoma; Cisplatin; Doxorubicin; Drug Thera

1981
Advanced ovarian cancer: brief intensive combination chemotherapy and second-look operation.
    Obstetrics and gynecology, 1981, Volume: 58, Issue:2

    Topics: Adult; Aged; Altretamine; Antineoplastic Agents; Carcinoma; Cisplatin; Cyclophosphamide; Doxorubicin

1981
In vivo and in vitro irreversible binding of hexamethylmelamine to liver and ovarian tumor macromolecules of mice.
    Biochemical pharmacology, 1981, May-15, Volume: 30, Issue:10

    Topics: Altretamine; Animals; Female; Kinetics; Mice; Mice, Inbred C57BL; Microsomes; Microsomes, Liver; Neo

1981
Prospective study with HEXA-CAF combination in ovarian carcinoma.
    Cancer chemotherapy and pharmacology, 1981, Volume: 5, Issue:3

    Topics: Altretamine; Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouraci

1981
Treatment of chemotherapy-resistant advanced ovarian cancer with a combination of cyclophosphamide, hexamethylmelamine, adriamycin, and cis-diamminedichloroplatinum (CHAP).
    Gynecologic oncology, 1981, Volume: 12, Issue:2 Pt 1

    Topics: Adenocarcinoma; Altretamine; Antineoplastic Agents; Cisplatin; Cyclophosphamide; Doxorubicin; Drug T

1981
Hexamethylmelamine and pentamethylmelamine tissue distribution in M5076/73A ovarian cancer-bearing mice.
    Cancer treatment reports, 1982, Volume: 66, Issue:1

    Topics: Altretamine; Animals; Antineoplastic Agents; Female; Kinetics; Mice; Neoplasms, Experimental; Ovaria

1982
Hexamethylmelamine distribution in patients with ovarian and other pelvic cancers.
    Cancer treatment reports, 1982, Volume: 66, Issue:2

    Topics: Adipose Tissue; Adult; Aged; Altretamine; Chromatography, Gas; Female; Humans; Kinetics; Middle Aged

1982
Influence of ascites on the pharmacokinetics of hexamethylmelamine and N-demethylated metabolites in ovarian cancer patients.
    European journal of cancer & clinical oncology, 1981, Volume: 17, Issue:12

    Topics: Adolescent; Adult; Age Factors; Aged; Altretamine; Ascites; Body Weight; Female; Humans; Kinetics; M

1981
Hexamethylmelamine-CAF (cyclophosphamide, methotrexate, and 5-FU) and cisplatin-CAF in refractory ovarian cancer.
    Cancer treatment reports, 1982, Volume: 66, Issue:5

    Topics: Adult; Aged; Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cis

1982
Treatment of ovarian cancer with a combination of cis-platinum, adriamycin, cyclophosphamide and hexamethylmelamine.
    Oncology, 1982, Volume: 39, Issue:4

    Topics: Acute Kidney Injury; Adult; Aged; Altretamine; Anemia; Antineoplastic Agents; Antineoplastic Combine

1982
Current concepts in cancer: ovary--treatment for stages III and IV. Chemotherapy in advanced disease.
    International journal of radiation oncology, biology, physics, 1982, Volume: 8, Issue:5

    Topics: Alkylating Agents; Altretamine; Antimetabolites, Antineoplastic; Antineoplastic Agents; BCG Vaccine;

1982
Current concepts in cancer: ovary--treatment for stages III and IV. The multimodal approach to the treatment of stage III ovarian carcinoma.
    International journal of radiation oncology, biology, physics, 1982, Volume: 8, Issue:5

    Topics: Altretamine; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Female; Humans; Ov

1982
Hexamethylmelamine and melphalan as salvage therapy in advanced ovarian carcinoma.
    Journal of surgical oncology, 1982, Volume: 21, Issue:3

    Topics: Adenocarcinoma, Papillary; Aged; Altretamine; Drug Therapy, Combination; Female; Humans; Melphalan;

1982
cis-Dichlorodiammineplatinum (II) and hexamethylmelamine in advanced ovarian carcinoma: a phase II study.
    European journal of cancer & clinical oncology, 1982, Volume: 18, Issue:11

    Topics: Adult; Aged; Altretamine; Cisplatin; Cystadenocarcinoma; Drug Evaluation; Drug Therapy, Combination;

1982
Hexamethylmelamine tissue concentrations in pelvic cancer patients.
    Therapeutic drug monitoring, 1980, Volume: 2, Issue:2

    Topics: Adult; Aged; Altretamine; Female; Humans; Middle Aged; Neoplasms; Ovarian Neoplasms; Triazines

1980
Determination of altretamine in human plasma with high-performance liquid chromatography.
    Journal of chromatography. B, Biomedical applications, 1994, Oct-03, Volume: 660, Issue:1

    Topics: Altretamine; Chromatography, High Pressure Liquid; Female; Food-Drug Interactions; Humans; Indicator

1994
Hexamethylmelamine/altretamine as second-line therapy for epithelial ovarian carcinoma.
    Gynecologic oncology, 1993, Volume: 51, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Altretamine; Carcinoma; Female; Humans; Middle Aged; Neoplasm Recurr

1993
Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis.
    Journal of the National Cancer Institute, 1993, Nov-03, Volume: 85, Issue:21

    Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamid

1993
[The use of Hexalen (Altretamin, hexamethyl melamine) in chemotherapy of extensive carcinoma of the ovaries].
    Voprosy onkologii, 2000, Volume: 46, Issue:4

    Topics: Altretamine; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Fema

2000
[Combination chemotherapy with hexamethylamine (Hexalen, Altretamine, Hexastat) and sarcolysine in advanced ovarian carcinoma].
    Voprosy onkologii, 2000, Volume: 46, Issue:5

    Topics: Adult; Aged; Altretamine; Antineoplastic Agents, Alkylating; Carcinoma; Chemotherapy, Adjuvant; Drug

2000
Hexamethylmelamine in alkylating agent-resistant ovarian carcinoma.
    Cancer, 1978, Volume: 42, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Alkylating Agents; Altretamine; Bone Marrow; Drug Resistance; Female; H

1978
Ovarian cancer. Effective treatment after alkylating-agent failure.
    JAMA, 1979, May-04, Volume: 241, Issue:18

    Topics: Adenocarcinoma; Adult; Aged; Altretamine; Cisplatin; Cystadenoma; Doxorubicin; Drug Therapy, Combina

1979
Variable oral absorption of hexamethylmelamine in man.
    Cancer treatment reports, 1978, Volume: 62, Issue:12

    Topics: Absorption; Administration, Oral; Adult; Aged; Altretamine; Female; Half-Life; Humans; Middle Aged;

1978
Combination chemotherapy for alkylator-resistant ovarian carcinoma: a preliminary report of a Southwest Oncology Group trial.
    Cancer treatment reports, 1979, Volume: 63, Issue:2

    Topics: Alkylating Agents; Altretamine; Antineoplastic Agents; Bone Marrow; Cisplatin; Doxorubicin; Drug Eva

1979
Phase II trial of cyclophosphamide, hexamethylmelamine, adriamycin, and cis-dichlorodiammineplatinum(II) combination chemotherapy in advanced ovarian carcinoma.
    Cancer treatment reports, 1979, Volume: 63, Issue:2

    Topics: Alkylating Agents; Altretamine; Antineoplastic Agents; Bone Marrow; Cisplatin; Cyclophosphamide; Dox

1979
The CHAD and HAD regimens in advanced ovarian cancer: combination chemotherapy including cyclophosphamide, hexamethylmelamine, adriamycin, and cis-dichlorodiammineplatinum(II).
    Cancer treatment reports, 1979, Volume: 63, Issue:2

    Topics: Adult; Aged; Alkylating Agents; Altretamine; Antineoplastic Agents; Bone Marrow; Cisplatin; Cyclopho

1979
Ovarian endometrioid carcinoma in an eleven-year-old child.
    Medical and pediatric oncology, 1979, Volume: 7, Issue:3

    Topics: Adenocarcinoma; Altretamine; Child; Cisplatin; Cyclophosphamide; Doxorubicin; Drug Therapy, Combinat

1979
Hexamethylmelamine: an evaluation of its role in the treatment of ovarian cancer.
    American journal of obstetrics and gynecology, 1979, Apr-01, Volume: 133, Issue:7

    Topics: Adult; Altretamine; Female; Hematologic Diseases; Humans; Ovarian Neoplasms; Peripheral Nervous Syst

1979
Acute leukemia after alkylating-agent therapy of ovarian cancer.
    The New England journal of medicine, 1977, Jul-28, Volume: 297, Issue:4

    Topics: Acute Disease; Alkylating Agents; Altretamine; Chlorambucil; Cyclophosphamide; Female; Fluorouracil;

1977
[Chemotherapy of the ovarian carcinoma (author's transl)].
    Strahlentherapie, 1977, Volume: 153, Issue:5

    Topics: Altretamine; Antineoplastic Agents; Chlorambucil; Cisplatin; Cyclophosphamide; Doxorubicin; Drug The

1977
Current concepts in the management of ovarian cancer.
    The Journal of reproductive medicine, 1978, Volume: 20, Issue:1

    Topics: Adult; Aged; Altretamine; Castration; Cisplatin; Cyclophosphamide; Doxorubicin; Female; Fluorouracil

1978
Hexamethylmelamine. An evaluation of its role in the therapy of cancer.
    Cancer, 1976, Volume: 38, Issue:1

    Topics: Altretamine; Animals; Breast Neoplasms; Carcinoma, Bronchogenic; Chemical Phenomena; Chemistry; Drug

1976
Chemotherapy in advanced ovarian cancer.
    National Cancer Institute monograph, 1975, Volume: 42

    Topics: Altretamine; Antineoplastic Agents; Cyclophosphamide; Dactinomycin; Doxorubicin; Drug Therapy, Combi

1975
Hexamethylmelamine in platinum-resistant ovarian cancer: how active?
    Gynecologic oncology, 1992, Volume: 47, Issue:3

    Topics: Altretamine; Carboplatin; Cisplatin; Drug Resistance; Female; Humans; Ovarian Neoplasms

1992
Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer.
    Gynecologic oncology, 1992, Volume: 47, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Altretamine; Carboplatin; Cisplatin; Drug Resistance; Female; Humans

1992
Hexamethylmelamine (altretamine). A discussion of drug action, pharmacology and clinical activity. Philadelphia, Pennsylvania, November 6, 1989. Proceedings.
    Cancer treatment reviews, 1991, Volume: 18 Suppl A

    Topics: Altretamine; Female; Humans; Ovarian Neoplasms

1991
Altretamine for ovarian cancer.
    The Medical letter on drugs and therapeutics, 1991, Aug-09, Volume: 33, Issue:850

    Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Ovarian Neoplasms; Pall

1991
[Study of vinorelbine (V) combined with hexamethylmelamine (H) (combination V-H) in adenocarcinoma of the ovary: results a phase I-IIA trial, NHO-88, of ARTAC "ovarian" group].
    Bulletin du cancer, 1991, Volume: 78, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherap

1991
Hexamethylmelamine (altretamine) activity as a single agent in previously untreated advanced ovarian cancer.
    Cancer treatment reviews, 1991, Volume: 18 Suppl A

    Topics: Administration, Oral; Altretamine; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Staging;

1991
Analysis of prognostic factors and survival in patients with ovarian cancer treated with second-line hexamethylmelamine (altretamine).
    Cancer treatment reviews, 1991, Volume: 18 Suppl A

    Topics: Altretamine; Female; Follow-Up Studies; Humans; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Pr

1991
[The potentials of combined chemotherapy in disseminated ovarian cancer].
    Akusherstvo i ginekologiia, 1991, Issue:2

    Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubici

1991
Hexamethylmelamine as a single second-line agent in ovarian cancer.
    Gynecologic oncology, 1990, Volume: 36, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Altretamine; Female; Humans; Middle Aged; Neoplasm Recurrence, Local

1990
Long-term follow-up of patients with advanced ovarian carcinoma treated with debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide. Gynecologic Oncology Group of the Comprehensive Cancer Center.
    Oncology, 1990, Volume: 47, Issue:2

    Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; C

1990
Ovarian cancer: what is poor prognosis disease?
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1990, Volume: 8, Issue:7

    Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubici

1990
Selecting drug combinations based on total equivalent dose (dose intensity)
    Journal of the National Cancer Institute, 1990, Sep-19, Volume: 82, Issue:18

    Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cyclophosphamid

1990
Prognostic factors in advanced epithelial ovarian cancer. (Gruppo Interregionale Cooperativo di Oncologia Ginecologica (GICOG)).
    British journal of cancer, 1990, Volume: 62, Issue:3

    Topics: Age Factors; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Cy

1990
The role of hexamethylmelamine in the combination chemotherapy of advanced ovarian cancer: a comparison of hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin (H-CAP) versus cyclophosphamide, doxorubicin, and cisplatin (CAP).
    American journal of clinical oncology, 1990, Volume: 13, Issue:5

    Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distribution; C

1990
Cisplatin induced neuropathy: central, peripheral and autonomic nerve involvement.
    Journal of neuro-oncology, 1990, Volume: 9, Issue:3

    Topics: Adenocarcinoma; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Autonomic Nervous Syste

1990
[Chemotherapy testing for human ovarian cancer using in vitro colony assay].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1985, Volume: 12, Issue:8

    Topics: Altretamine; Antineoplastic Agents; Bleomycin; Cell Division; Cells, Cultured; Cisplatin; Colony-For

1985
Small cell carcinoma of the ovary: a rapidly lethal tumor occurring in the young.
    Gynecologic oncology, 1985, Volume: 22, Issue:2

    Topics: Adolescent; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Small

1985
Modulation and intensification of a cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin ovarian cancer regimen.
    Obstetrics and gynecology, 1989, Volume: 73, Issue:3 Pt 1

    Topics: Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclo

1989
Phase II evaluation of peroral carmofur, cyclophosphamide, and hexamethylmelamine as a second-line therapy in advanced epithelial ovarian carcinoma.
    Gynecologic oncology, 1989, Volume: 34, Issue:1

    Topics: Administration, Oral; Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carc

1989
Schedule and dosage modification of a cyclophosphamide, hexamethylmelamine, doxorubicin, cisplatin combination chemotherapy regimen for refractory ovarian cancer.
    European journal of cancer & clinical oncology, 1989, Volume: 25, Issue:9

    Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubici

1989
Management of recurrent ovarian carcinoma.
    American journal of clinical oncology, 1989, Volume: 12, Issue:3

    Topics: Adenocarcinoma, Mucinous; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplat

1989
Treatment of advanced ovarian cancer with sequential combination chemotherapy.
    Cancer, 1987, Nov-01, Volume: 60, Issue:9

    Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamid

1987
Combined modality treatment for stage III ovarian carcinoma.
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 1985, Volume: 3, Issue:3

    Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Altretamine; Antineoplastic Combined Chemothe

1985
Malignant mixed mesodermal tumors of the uterus and ovary treated with cisplatin-based combination chemotherapy.
    Gynecologic oncology, 1986, Volume: 25, Issue:3

    Topics: Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxo

1986
Hexamethylmelamine, cyclophosphamide, adriamycin, cis-platinum chemotherapy as initial and second-line treatment of advanced ovarian carcinoma.
    Oncology, 1986, Volume: 43, Issue:1

    Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamid

1986
Hexamethylmelamine, methotrexate, 5-fluorouracil as second line chemotherapy after platinum for epithelial ovarian malignancies.
    Gynecologic oncology, 1986, Volume: 23, Issue:3

    Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Combined Modali

1986
[Chemotherapy in 143 advanced epithelial cancers of the ovary. Experience at the Hôtel-Dieu of Quebec and Hôpital Saint-Antoine (Paris)].
    Journal de gynecologie, obstetrique et biologie de la reproduction, 1986, Volume: 15, Issue:1

    Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cyclophosphamide;

1986
Changes in erythropoiesis due to radiation or chemotherapy as studied by flow cytometric determination of peripheral blood reticulocytes.
    Histochemistry, 1986, Volume: 84, Issue:4-6

    Topics: Altretamine; Animals; Blood Cell Count; Cisplatin; Cyclophosphamide; Dose-Response Relationship, Dru

1986
Superior efficacy of trimelamol to hexamethylmelamine in human ovarian cancer xenografts.
    Cancer chemotherapy and pharmacology, 1986, Volume: 18, Issue:2

    Topics: Altretamine; Animals; Antineoplastic Agents; Female; Humans; Kinetics; Mice; Mice, Nude; Neoplasm Tr

1986
Prognostic factors: cisplatin regimens for patients with ovarian cancer after failure of chemotherapy.
    Obstetrics and gynecology, 1987, Volume: 69, Issue:1

    Topics: Adult; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dox

1987
Acute myelocytic leukemia in a patient treated with hexamethylmelamine.
    The American journal of the medical sciences, 1986, Volume: 292, Issue:6

    Topics: Aged; Altretamine; Female; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Ovarian Neo

1986
Computed tomography prior to surgery for ovarian carcinoma.
    The Australian & New Zealand journal of obstetrics & gynaecology, 1986, Volume: 26, Issue:3

    Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; C

1986
Hexamethylmelamine in ovarian cancer after failure of cisplatin-based multiple-agent chemotherapy.
    Gynecologic oncology, 1987, Volume: 27, Issue:2

    Topics: Adenocarcinoma; Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin;

1987
[Chemotherapy of epithelial ovarian cancer: CHexUP versus thio-tepa].
    Zhonghua fu chan ke za zhi, 1987, Volume: 22, Issue:1

    Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cyclophosphamide;

1987
Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy.
    Proceedings of the National Academy of Sciences of the United States of America, 1987, Volume: 84, Issue:14

    Topics: Adult; Aged; Altretamine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Car

1987
The treatment of advanced stage ovarian carcinoma with a combination of chemotherapy, radiotherapy, and radiosensitizer: report of a pilot study from the National Cancer Institute.
    International journal of radiation oncology, biology, physics, 1987, Volume: 13, Issue:8

    Topics: Adult; Aged; Altretamine; Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Cyclophospham

1987
Cyclophosphamide, hexamethylmelamine, adriamycin and cisplatin combination chemotherapy in mixed mesodermal sarcoma of the female genital tract.
    European journal of cancer & clinical oncology, 1987, Volume: 23, Issue:8

    Topics: Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxo

1987
Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration.
    Annals of internal medicine, 1988, Volume: 108, Issue:2

    Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Cycl

1988
Chemotherapeutic and surgical induction of pathological complete remission and whole abdominal irradiation for consolidation does not enhance the cure of stage III ovarian carcinoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1988, Volume: 6, Issue:3

    Topics: Abdomen; Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cispla

1988
An interaction between cytostatic and anticonvulsant drugs.
    Clinical pharmacology and therapeutics, 1988, Volume: 43, Issue:4

    Topics: Adenocarcinoma, Papillary; Adult; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carba

1988
The role of cytoreduction in ovarian cancer.
    European journal of gynaecological oncology, 1988, Volume: 9, Issue:2

    Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; C

1988
Advanced carcinoma of the ovary with central nervous system relapse.
    Gynecologic oncology, 1988, Volume: 30, Issue:3

    Topics: Adenocarcinoma; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms;

1988
The treatment of advanced ovarian carcinoma (I): clinical variables associated with prognosis.
    Gynecologic oncology, 1988, Volume: 30, Issue:3

    Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Combined Modality

1988
Role of hexamethylmelamine in the treatment of ovarian cancer: where is the needle in the haystack?
    Journal of the National Cancer Institute, 1988, Sep-21, Volume: 80, Issue:14

    Topics: Altretamine; Cyclophosphamide; Female; Humans; Ovarian Neoplasms; Triazines

1988
The cyclophosphamide, hexamethylmelamine, 5 fluorouracil (CHF) regimen in the treatment of advanced and recurrent ovarian cancer.
    Gynecologic oncology, 1985, Volume: 20, Issue:1

    Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy;

1985
HAC-Cytoxan (cyclophosphamide) chemotherapy for ovarian carcinoma. Alternating chemotherapy with intensification.
    Cancer, 1985, May-15, Volume: 55, Issue:10

    Topics: Adenocarcinoma; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclop

1985
Recurrent ovarian carcinoma: retreatment utilizing combination chemotherapy including cis-diamminedichloroplatinum in patients previously responding to this agent.
    Gynecologic oncology, 1985, Volume: 21, Issue:2

    Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modali

1985
Single agent vs. combination chemotherapy for ovarian cancer.
    American journal of clinical oncology, 1985, Volume: 8, Issue:1

    Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospha

1985
Intraperitoneal chemotherapy for advanced ovarian cancer.
    American journal of obstetrics and gynecology, 1985, Jun-15, Volume: 152, Issue:4

    Topics: Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Doxorubici

1985
Six-drug chemotherapy (hexamethylmelamine, doxorubicin, cisplatin, cyclophosphamide, methotrexate, and 5-FU; CHAMP-5) for ovarian carcinoma: alternating sequences of combination regimens.
    Cancer treatment reports, 1985, Volume: 69, Issue:6

    Topics: Adenocarcinoma; Age Factors; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin;

1985
Mullerian inhibiting substance reduction of colony growth of human gynecologic cancers in a stem cell assay.
    Gynecologic oncology, 1985, Volume: 22, Issue:2

    Topics: Adenocarcinoma; Altretamine; Anti-Mullerian Hormone; Ascitic Fluid; Carcinoma; Chromatography, Affin

1985
Hexamethylmelamine, methotrexate and 5-fluorouracil (HMF) for progressive ovarian carcinoma during therapy with cis-platinum, cyclophosphamide +/- doxorubicin.
    Gynecologic oncology, 1985, Volume: 22, Issue:2

    Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamid

1985
Response of ovarian cancer to combined cytotoxic agents in the subrenal capsule assay: Part I.
    Obstetrics and gynecology, 1985, Volume: 66, Issue:5

    Topics: Aclarubicin; Adolescent; Adult; Aged; Altretamine; Animals; Antibiotics, Antineoplastic; Antineoplas

1985
The treatment of ovarian cancer by a multimodality approach: remission induction with chemotherapy--hexa PAMP and PAMP regimens--followed by whole-abdominal radiation.
    Onkologie, 1985, Volume: 8, Issue:6

    Topics: Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Female; Humans;

1985